Shares of pharmaceutical companies declined after U.S. President Donald Trump announced plans to lower U.S. prescription drug ...

Gain key insights from Lisata Therapeutics' Q1 2025 earnings call, including clinical updates on Certepetide, strategic milestones, and robust ...

Q1 2025 net product revenue for ZORYVE® (roflumilast) was $63.8 million, a 196% increase compared to Q1 of 2024, and a 2% decrease compared to Q4 of 2024, due to typical first-quarter deductible reset ...

Lefkofsky announced a three-year, $200 million data and modeling license agreement with AstraZeneca and Pathos to build the world’s largest foundation model in oncology. This agreement increased ...

Q1 2025 net product revenue for ZORYVE ® (roflumilast) was $63.8 million, a 196% increase compared to Q1 of 2024, and a 2% decrease compared to Q4 of 2024, due to typical first-quarter deductible ...

Mergers and acquisitions (M&As) in the biopharmaceutical industry surged 101% in total deal value in the first quarter (Q1) ...